NAS:GLSI (USA)
Â
Ordinary Shares
$
14.15
-2.25 (-13.79%)
10:08 PM EST
Business Description
Greenwich LifeSciences Inc
NAICS : 541714
SIC : 2834
ISIN : US3968791083
Share Class Description:
GLSI: Ordinary SharesTotal Employee Number:
13Description
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.5 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -32.2 | |||||
3-Year EPS without NRI Growth Rate | -32.8 | |||||
3-Year FCF Growth Rate | -15.1 | |||||
3-Year Book Growth Rate | -71 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.27 | |||||
9-Day RSI | 23.25 | |||||
14-Day RSI | 29.09 | |||||
3-1 Month Momentum % | -4.65 | |||||
6-1 Month Momentum % | 9.82 | |||||
12-1 Month Momentum % | 101.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.01 | |||||
Quick Ratio | 2.01 | |||||
Cash Ratio | 2.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.6 | |||||
Shareholder Yield % | -8.51 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -1030.26 | |||||
ROA % | -412.6 | |||||
ROIC % | -4826.28 | |||||
3-Year ROIIC % | -1715.49 | |||||
ROCE % | -1036.65 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 39.08 | |||||
Price-to-Tangible-Book | 39.32 | |||||
EV-to-EBIT | -8.95 | |||||
EV-to-EBITDA | -8.95 | |||||
EV-to-FCF | -15.34 | |||||
| Price-to-Net-Current-Asset-Value | 39.32 | |||||
| Price-to-Net-Cash | 39.32 | |||||
Earnings Yield (Greenblatt) % | -11.17 | |||||
FCF Yield % | -6.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GLSI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Greenwich LifeSciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.57 | ||
| Beta | 1.77 | ||
| 3-Year Sharpe Ratio | 0.61 | ||
| 3-Year Sortino Ratio | 1.77 | ||
| Volatility % | 150.14 | ||
| 14-Day RSI | 29.09 | ||
| 14-Day ATR ($) | 2.249468 | ||
| 20-Day SMA ($) | 20.135 | ||
| 12-1 Month Momentum % | 101.73 | ||
| 52-Week Range ($) | 7.78 - 34.1 | ||
| Shares Outstanding (Mil) | 14.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Greenwich LifeSciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Greenwich LifeSciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-18 09:00 | In 151 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 24 days | ||
| First quarter earnings results for 2026 | 2026-06-04 | 24.29 (-0.04%) | ||
| Annual report for 2025 | 2026-06-01 | 26.18 (-10.79%) | ||
| General meeting for 2025 | 2025-12-18 09:00 | 10.74 (+3.27%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 8.20 (-1.56%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 11.78 (-5.76%) | ||
| First quarter earnings results for 2025 | 2025-05-20 | 10.18 (+5.27%) | ||
| Annual report for 2024 | 2025-04-15 | 9.28 (-7.75%) |
Show
Entries
Greenwich LifeSciences Inc Frequently Asked Questions
What is Greenwich LifeSciences Inc(GLSI)'s stock price today?
The current price of GLSI is $14.16. The 52 week high of GLSI is $34.10 and 52 week low is $7.78.
When is next earnings date of Greenwich LifeSciences Inc(GLSI)?
The next earnings date of Greenwich LifeSciences Inc(GLSI) is 2026-08-14 Est..
Does Greenwich LifeSciences Inc(GLSI) pay dividends? If so, how much?
Greenwich LifeSciences Inc(GLSI) does not pay dividend.
Guru Commentaries on NAS:GLSI
No articles.
Press Release
Articles on Greenwich LifeSciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers